Atlas Trials

A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients

Clinical trial NCT03867123 · COMPLETED

Trial details

NCT number
NCT03867123
Sponsor
Laminar Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Glioblastoma (GBM)
Start date
2018-12-04
Primary completion
2020-07-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.